Asterias announces continued motor function improvement in phase 1/2a trial for acute SCI

Six AIS-A quadriplegic volunteers received 10 million  AST-OPC1 cells in Asterias Biotherapeutics SCIstar trial. For the five patients who have completed at least 6 months of follow-up all have seen improvements in their motor function,

Read more…

Asterias announces continued motor function improvement in phase 1/2a trial for acute SCI